Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02228681
Recruitment Status : Active, not recruiting
First Posted : August 29, 2014
Results First Posted : May 24, 2019
Last Update Posted : September 30, 2021
Novartis Pharmaceuticals
Information provided by (Responsible Party):
GOG Foundation ( Gynecologic Oncology Group )

Brief Summary:
The main purpose of this study is to evaluate the effectiveness of the combination of the drugs Everolimus and Letrozole compared to Tamoxifen and Medroxyprogesterone acetate in treating endometrial cancer and to determine the types and severity of side effects caused by treatment with these drug combinations.

Condition or disease Intervention/treatment Phase
Advanced, Persistent, or Recurrent Endometrial Cancer Drug: Everolimus Drug: Tamoxifen Drug: Letrozole Drug: Medroxyprogesterone Acetate Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 74 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma
Study Start Date : February 2015
Actual Primary Completion Date : January 2018

Arm Intervention/treatment
Experimental: Everolimus and Letrozole
Everolimus 10 mg daily and Letrozole 2.5 mg PO daily
Drug: Everolimus
10mg daily by mouth
Other Name: RAD001

Drug: Letrozole
2.5mg once a day by mouth
Other Name: Femara®

Active Comparator: Hormonal Therapy
Tamoxifen 20 mg PO BID; on alternating weeks (even numbered) weeks, Medroxyprogesterone Acetate 200 mg PO daily with Tamoxifen 20 mg PO BID
Drug: Tamoxifen
20 mg daily by mouth on alternating weeks (even numbered) weeks
Other Name: Nolvadex®

Drug: Medroxyprogesterone Acetate
200 mg daily by mouth

Primary Outcome Measures :
  1. Frequency of Response [ Time Frame: From date of randomization until the date of first documented progression or date of death , up to 3 years. ]
    A confirmed complete or partial response as defined by RECIST 1.1 was considered a response. "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Secondary Outcome Measures :
  1. Median Progression-free Survival [ Time Frame: Tumor measurements were done at 8 and 16 weeks after initiating treatment and then every 12 weeks and compared with baseline measurements prior to treatment. Measurements are continued until disease progression is documented or death. ]
    Progression-free Survival is defined as the duration alive from study entry until progression is documented, or death; whichever comes sooner. Progressive disease is defined as at least a 5 mm absolute increase and a 20% relative increase in the sum of measurable target lesions' longest dimensions relative to the smallest sum at baseline or on study or the appearance of new lesions or unequivocal progression of existing non-target lesions.

  2. Frequency and Severity of CTCAE (Common Toxicity Criteria for Adverse Events) Version 4 [ Time Frame: Assessed throughout the treatment period and for 30 days after discontinuation of treatment. Treatment continues until progression of disease. ]
    Maximum grade of physician assessed adverse events graded and categorized using Common Toxicity Criteria for Adverse Events (CTCAE) version 4

  3. Median Survival [ Time Frame: Following treatment discontinuation, patients are followed quarterly for 2 years, semi-annually for 3 more years, annually thereafter. ]
    Survival is defined as the duration alive from study entry until death.

Other Outcome Measures:
  1. Hormone Receptor Immunohistochemistry [ Time Frame: At study entry ]
    To determine if relevant biomarkers correlate with response to treatment in each of the two arms. Unstained sections of tumor tissue will be used for hormone receptor (estrogen receptor-alpha, estrogen receptor-beta, progesterone receptor-A, progesterone receptor B and the G protein-coupled estrogen receptor, GPR-30) immunohistochemistry.

  2. mTOR Pathway Immunohistochemistry [ Time Frame: At study entry ]
    To determine if relevant biomarkers correlate with response to treatment in each of the two arms. Unstained sections of tumor tissue will be used for mTOR pathway (including phosphorylated S6 ribosomal protein, PTEN, total and phosphorylated AKT, total and phosphorylated mTOR, and phospho-ERK1/2) immunohistochemistry

  3. Mutation Analysis [ Time Frame: At study entry ]
    To determine if relevant biomarkers correlate with response to treatment in each of the two arms. Unstained sections of tumor tissue and DNA extracted from whole blood will be used for mutational analysis (including PTEN, PIK3CA, KRAS, and CTNNB1 (beta-catenin) performed using a sequencing panel assay.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically confirmed advanced (FIGO Stage III or IV), persistent, or recurrent endometrial carcinoma, which is not likely to be curable by surgery or radiotherapy. Histologic documentation of the recurrence is not required.
  • All patients must have measurable disease. Measurable disease is defined by RECIST version 1.1). Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be greater than or equal to 10 mm when measured by CT, MRI or caliper measurement by clinical exam; or greater than or equal to 20 mm when measured by chest x-ray. Lymph nodes must be greater than or equal to 15 mm in short axis when measured by CT or MRI (See section 8).
  • Patients must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST 1.1 (Section 8.1). Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy.
  • Prior chemoradiotherapy for a pelvic recurrence is permitted. Prior chemotherapy in the adjuvant setting for Stage I, II or III disease is permitted.

Note: No prior chemotherapy in the setting of Stage IV disease is permitted unless the patient was without evidence of disease at the completion of chemotherapy and had at least six months of progression-free survival since the completion of chemotherapy.

Regardless of circumstances, no more than one prior chemotherapy regimen (including chemo-radiotherapy) is permitted.

  • Patient must be able to take p.o. medications.
  • Performance status must be 0-1.
  • Patients must have adequate organ and marrow function as defined below:

NOTE: Institutional/laboratory upper limit of normal = ULN Institutional/laboratory lower limit of normal = LLN

  • Bone marrow function:

    • Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl
    • Platelets greater than or equal to 100,000 cells/mcl
    • Hemoglobin greater than or equal to 9 g/dL
  • Coagulation

    • INR less than or equal to 1.5 x ULN (or in range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin).

  • Renal function:

    • Creatinine less than or equal to 1.5 x ULN

  • Hepatic function:

    • Bilirubin less than or equal to 1.5 x ULN
    • ALT and AST less than or equal to 3 x ULN
    • Alkaline phosphatase less than or equal to 2.5 x ULN
    • Albumin greater than or equal to 2.8 g/dL
  • Lipid panel:

    • Fasting serum cholesterol less than or equal to 300 mg/dL
    • Fasting triglycerides less than or equal to 300 mg/
  • At least 4 weeks must have elapsed since the patient underwent any major surgery (e.g., major: hysterectomy, resection of a lung nodule; minor: central venous access catheter placement).
  • At least 4 weeks must have elapsed since the patient received any radiation therapy.
  • Patients who have met the pre-entry requirements specified in Section 7.0
  • Patients must have signed an approved informed consent and authorization permitting release of personal health information.
  • All patients must be at least 18 years of age
  • Patients of childbearing potential must have a negative serum pregnancy test prior to the study entry and be practicing a highly effective form of contraception.

During the study treatment and for 8 weeks after stopping the treatment. Highly effective contraception methods include combination of any two of the following:

  • Use of oral, injected or implanted hormonal methods of contraception or;
  • Placement of an intrauterine device (IUD) or intrauterine system (IUS);
  • Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository;
  • Total abstinence or;
  • Male/female sterilization. Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child-bearing potential.

Exclusion Criteria:

  • Patients who have previously received everolimus, any another mTOR inhibitor or any agent targeting the PI3K/AKT/mTOR pathway.
  • Known intolerance or hypersensitivity to Everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus)
  • Patients who have previously received hormonal therapy for endometrial cancer.
  • Patients with concomitant invasive malignancy or a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the past five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol.
  • Patients receiving chronic treatment with systemic steroids or another immunosuppressive agent.
  • Patients with active or uncontrolled systemic infection.
  • Uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate therapy. Patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and anti-diabetic treatment must be monitored closely throughout the trial and adjusted as necessary.
  • Known severely impaired lung function, including:

    • CTCAE grade 2 (or greater) hypoxia (decreased oxygen saturation with exercise [e.g., pulse oximeter <88%]; intermittent supplemental oxygen)

  • Patients with a known history of cardiac disease. This includes:
  • Uncontrolled hypertension, defined as systolic greater than 150 mm Hg or diastolic greater than 90 mm Hg despite antihypertensive medications.
  • Myocardial infarction or unstable angina within 6 months prior to registration.
  • New York Heart Association (NYHA) Class II or greater congestive heart failure.
  • History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or serious cardiac arrhythmia requiring medication. This does not include asymptomatic atrial fibrillation with controlled ventricular rate.
  • Cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) within 6 months prior to the first date of study therapy.
  • Patients who are pregnant or breast-feeding.
  • Patients with known central nervous system metastases.
  • Patients with known human immunodeficiency virus (HIV) infection.
  • Patients with an impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease; uncontrolled nausea, vomiting and/or diarrhea; malabsorption syndrome; clinical signs and symptoms of gastrointestinal obstruction; and/or patients who require parenteral hydration and/or nutrition).
  • Patients who plan to receive live attenuated vaccines within 1 week of start of everolimus and during the study. Patient should also avoid close contact with others who have received live attenuated vaccines. Examples of live attenuated vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella and TY21a typhoid vaccines.
  • Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder or coagulopathy.
  • Patients who are currently part of or have participated in any clinical investigation with an investigational drug within 30 days prior to dosing.
  • Patients must be able to follow concomitant medication restrictions:

    • Avoid the use of strong CYP3A/PgP inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir, telithromycin, ritonavir, indinavir, nelfinavir, voriconazole).
    • Use caution when co-administered with moderate CYP3A4/PgP inhibitors (e.g., amprenavir, fosamprenavir, aprepitant, erythromycin, fluconazole, verapamil, diltiazem).
    • Grapefruit, grapefruit juice, and other foods known to inhibit cytochrome P450 and PgP activity may increase everolimus exposures and should be avoided during treatment.
    • Avoid the use of concomitant strong CYP3A4/PgP inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, and phenobarbital).
    • St. John's Wort may decrease everolimus exposure unpredictably and should be avoided.
  • Patients with active hepatitis B or C. Screening for hepatitis B

Prior to randomization/start of everolimus, the following three categories of patients should be tested for hepatitis B viral load and serologic markers, that is, HBsAg, HBcAb, HBsAb and quantitative hepatitis B DNA PCR (HBV-DNA):

• All patients who currently live in (or have lived in) Asia, Africa, Central and South America, Eastern Europe, Spain, Portugal and Greece.


  • Patients with any of the following risk factors:
  • known or suspected past hepatitis B infection,
  • blood transfusion(s) prior to 1990,
  • current or prior IV drug users,
  • current or prior dialysis,
  • household contact with hepatitis B infected patient(s),
  • current or prior high-risk sexual activity,
  • body piercing or tattoos,
  • mother known to have hepatitis B
  • history suggestive of hepatitis B infection, e.g., dark urine, jaundice, right upper quadrant pain.
  • Additional patients at the discretion of the investigator The management guidelines, in Section 6, are provided according to the results of the baseline assessment of viral load and serological markers for hepatitis B.

Screening for hepatitis C

Patients with any of the following risk factors for hepatitis C should be tested using quantitative RNA-PCR:

  • known or suspected past hepatitis C infection (including patients with past interferon 'curative' treatment),
  • blood transfusions prior to 1990,
  • current or prior IV drug users,
  • current or prior dialysis,
  • household contact of hepatitis C infected patient(s),
  • current or prior high-risk sexual activity,
  • body piercing or tattoos. At the discretion of the investigator, additional patients may also be tested for hepatitis C.

The management guidelines, in Section 6 are provided according to the results of the baseline assessment of hepatitis C viral load.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02228681

Show Show 26 study locations
Sponsors and Collaborators
Gynecologic Oncology Group
Novartis Pharmaceuticals
Layout table for investigator information
Study Chair: Brian Slomovitz, MD Gynecologic Oncology Group
  Study Documents (Full-Text)

Documents provided by GOG Foundation ( Gynecologic Oncology Group ):
Layout table for additonal information
Responsible Party: Gynecologic Oncology Group Identifier: NCT02228681    
Other Study ID Numbers: GOG-3007
CRAD001CUS236T ( Other Identifier: Novartis Pharmaceuticals )
First Posted: August 29, 2014    Key Record Dates
Results First Posted: May 24, 2019
Last Update Posted: September 30, 2021
Last Verified: September 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Medroxyprogesterone Acetate
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents
Contraceptives, Oral, Hormonal
Contraceptives, Oral
Contraceptive Agents, Female